BioMedNewsBreaks

MondayApr 14, 2025 9:20 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Halts Some U.S. Product Plans in China Over Tariff Escalation

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, announced it will pause select initiatives within its e-commerce development program due to China’s recent tariff hikes on U.S.-produced goods. The affected efforts include the planned launch of the Florida Sunshine brand of vitamins and supplements, which would face high import costs and diminished competitiveness in the Chinese market. The company launched its cross-border program in April 2023 to help U.S. businesses reach Chinese consumers via platforms like Alibaba’s Tmall. Despite the setback, NextPlat will continue offering OPKO Health Europe’s (NASDAQ: OPK) non-U.S.-made products in China, including nutraceuticals, supplements and upcoming pet…

Continue Reading

FridayApr 11, 2025 3:30 pm

BioMedNewsBreaks — Adageis Brings Power of AI to the Frontlines of Healthcare

Adageis is positioning as a key player in healthcare financial technology, offering an innovative AI-powered ProActive Care Platform that helps providers transition from fee-for-service to value-based care models. Its Patented Risk Engine (“PRE”) enables predictive analytics for optimizing revenue, improving patient outcomes, and simplifying insurance complexities. By seamlessly integrating with widely used systems, the platform delivers an easy-to-use, efficient, and scalable solution for value-based care revenue optimization. With streamlined onboarding, projected growth and funding, Adageis is poised for significant expansion in the healthcare technology space, offering investors a compelling opportunity to participate in the evolving $19.27 billion healthcare AI market. To…

Continue Reading

FridayApr 11, 2025 8:50 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures Patent in Macao for AVERSA Abuse-Deterrent Technology

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has been granted a patent in Macao for its AVERSA™ abuse-deterrent transdermal technology. The patent, titled “Abuse and Misuse Deterrent Transdermal Systems,” was granted on Feb. 11 and recorded in Macao’s Official Bulletin on Mar. 5. This adds to Nutriband’s global IP portfolio, with coverage now spanning 46 countries and both SARs of China. AVERSA is designed to reduce abuse, diversion and accidental exposure of transdermal drugs like opioids. Nutriband is advancing development of AVERSA Fentanyl with partner Kindeva Drug Delivery, aiming to commercialize the world’s first abuse-deterrent fentanyl patch…

Continue Reading

ThursdayApr 10, 2025 9:10 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Appoints Oncology Expert Dr. Guy Travis Clifton as Chief Medical Officer

Calidi Biotherapeutics (NYSE American: CLDI) has named Dr. Guy Travis Clifton as Chief Medical Officer, Consultant and Advisor. The appointment comes as Calidi advances clinical development of CLD-201, a virotherapy for solid tumors, following a recently filed Investigational New Drug application. Dr. Clifton brings over 17 years of oncology and clinical trial expertise, including leadership roles at Parthenon Therapeutics and service as a surgical oncologist in the U.S. Army. His extensive experience in immunotherapy is expected to bolster Calidi’s efforts in developing stem cell-based and enveloped virus cancer therapies. To view the full press release, visit: https://ibn.fm/LQkJV About Calidi Biotherapeutics…

Continue Reading

WednesdayApr 09, 2025 9:59 am

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL) Subsidiary Wins UK Government Contract for Satellite Communication Devices

NextPlat (NASDAQ: NXPL, NXPLW) announced that its subsidiary, Global Telesat Communications Ltd, has secured its first contract with a central UK government department to supply Iridium Push-To-Talk (PTT) satellite communication devices and recurring airtime services. The devices, designed for secure and reliable global communication, will support government staff engaged in policy development and coordination. Initial shipments are scheduled for the second quarter and will not be impacted by recent U.S. tariffs.  To view the full press release, visit https://ibn.fm/DJmcP  About NextPlat Corp  NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology…

Continue Reading

WednesdayApr 09, 2025 9:37 am

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) and UAV Corp (OTC: UMAV) Sign MOU to Develop Airborne Biohazard Detection and Response Systems 

Fifty 1 Labs (OTC: FITY), via its subsidiary Genetic Networks, has entered a Memorandum of Understanding with UAV Corp (OTC: UMAV) to jointly develop technologies for detecting and countering nuclear, chemical, and biological threats. The partnership combines UAV Corp’s aerial platforms with Genetic Networks’ GeneScape™ technology to create airborne detection and countermeasure systems. Initial testing will begin on UAV Corp’s airship in Wewahitchka, with both companies also leveraging Department of Defense relationships and exploring future contract opportunities.  To view the full press release, visit https://ibn.fm/Fp9K1  About Fifty 1 Labs, Inc.  Fifty 1 Labs, Inc. (OTC: FITY), a Nevada corporation based…

Continue Reading

FridayApr 04, 2025 3:38 pm

BioMedNewsBreaks — Adageis Positioned to Scale Impact in Health Technology Landscape

Adageis is a forward-thinking healthcare technology company that is transforming patient care with AI-driven software solutions. The company recently secured $2 million in seed financing and plans to utilize the funding to support upgrades to its backend infrastructure, expand Electronic Health Record (“EHR”) system connectivity, and increase sales efforts to promote rapid growth. Its flagship ProActive Care Platform assists healthcare providers in the transition to value-based care, improving patient focus, reducing costs, and increasing reimbursements. Adageis’ technology seamlessly integrates with over 90 EHR systems, enabling smooth implementation without disrupting workflows. By leveraging AI, the company simplifies insurance complexities and supports the…

Continue Reading

FridayApr 04, 2025 10:34 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Signs Partnership Deal With Charlotte FC to Boost Brand Visibility 

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has entered into an Associate Partnership agreement with Charlotte FC to raise awareness of its flagship brands, including AI Tape and AVERSA. The company plans to leverage the partnership to enhance exposure for AI Tape, which is manufactured in the Charlotte region through its Pocono Pharmaceutical subsidiary. Nutriband also aims to spotlight its AVERSA platform, touted as a potential first-in-class abuse-deterrent patch for chronic pain management.  To view the full press release, visit https://ibn.fm/2i77f  About Nutriband Inc.  Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products.…

Continue Reading

ThursdayApr 03, 2025 3:24 pm

BioMedNewsBreaks — Sunshine Biopharma Inc. (NASDAQ: SBFM) Secures $2.46M in Registered Direct 

Sunshine Biopharma (NASDAQ: SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, has closed its previously announced registered direct offering with institutional investors of approximately $2.46 million shares of common stock and pre-funded warrants at a price of $2.07 per share of common stock. The company received aggregate gross proceeds of approximately $2.46 million from the offering, of which it intends to use the net for general corporate purposes and working capital. Aegis Capital Corp. acted as exclusive placement agent for the offering. Sichenzia Ross Ference Carmel LLP acted as…

Continue Reading

WednesdayApr 02, 2025 3:35 pm

BioMedNewsBreaks — Polyrizon Ltd. (NASDAQ: PLRZ) Secures $17M in Private Placement 

Polyrizon (NASDAQ: PLRZ), a biotech company specializing in innovative intranasal hydrogels, has closed its previously announced private placement of approximately $17.0 million ordinary shares and/or pre-funded and investor warrants at a price of $0.48 per ordinary unit. The company secured approximately $17.0 million in aggregate gross proceeds from the offering and intends to use the net, together with its existing cash, for general corporate purposes and working capital. Aegis Capital Corp. acted as exclusive placement agent for the private placement. Greenberg Traurig, P.A. acted as counsel to the company, and Kaufman & Canoles, P.C. acted as counsel to Aegis.  To…

Continue Reading